XML 87 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative and Licensing Arrangements - Amgen (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Apr. 20, 2022
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2019
USD ($)
product
Ordinary Shares      
Research and Development Arrangement, Contract to Perform for Others      
Share price, ADS (in dollars per share) | $ / shares $ 132.74    
Proceeds from ADS shares $ 2,109,902    
Amgen, Inc | Beigene Ltd      
Research and Development Arrangement, Contract to Perform for Others      
Minority interest in investment (as a percent) 20.50%    
Product Revenue | Product Concentration Risk | Amgen, Inc      
Research and Development Arrangement, Contract to Perform for Others      
Concentration risk, percentage   100.00%  
Amgen, Inc      
Research and Development Arrangement, Contract to Perform for Others      
Number of products company has the right to retain | product     1
Product retention period     5 years
Maximum cash and development services commitment   $ 1,250,000 $ 1,250,000
Shares issued (in shares) | shares 15,895,001    
Per share acquisition price (in dollars per share) | $ / shares $ 174.85    
Fair value of cost share liability $ 601,857    
Payments to acquire equity interest 2,779,241    
Fair value of equity investments issued 2,162,407    
Fair value of financing commitment $ 616,834    
Amgen, Inc | Minimum      
Research and Development Arrangement, Contract to Perform for Others      
Commercialization term (years)     5 years
Amgen, Inc | Maximum      
Research and Development Arrangement, Contract to Perform for Others      
Commercialization term (years)     7 years
Royalties receiving period     5 years